Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
Lymphoma
Primary: Participants' Response — 23; 2; 3; 1 participants
Phase 2 N=67 Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Sleep Disorder · Primary Insomnia
Primary: Wake After Sleep Onset During Hours 3 to 7 Post-dose (WASO 3-7) — -40.19; -48.79; -50.17; -49.34 minutes — p=0.0118
Phase 2 N=15 PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — 2.624; 2.626; 2.585; 2.579 L
Phase 2 N=41 Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Time to Progression (TTP) — 26.94 Months
Phase 2 N=20 Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
Phase 2 N=25 A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
Genetic Disorders · Hereditary Angioedema
Primary: HAE Attacks/Week — 0.9; 0.4 attacks/week
Phase 2 N=183 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
Influenza
Primary: Number of Participants Reporting Vaccine-associated Unsolicited Non-serious Adverse Events — 2; 3; 2; 0 participants
Phase 2 N=75 Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Breast Neoplasms · Neoplasm Metastasis
Primary: Progression-Free Survival (PFS) Rate — 39.6 percentage of participants
Phase 2 N=420 Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period — 2.90; 2.49; 3.61; 2.68…
Phase 2 N=21 Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis
Primary: Absolute Change From Baseline in Lung Clearance Index (LCI) — 0.77; -1.30 ratio — p=0.0004
Phase 2 N=38 The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
Vitrectomy
Primary: Ocriplasmin Activity Levels in Vitreous Samples Obtained at the Beginning of Vitrectomy. — 11597.711; 8108.726; 2610.563; 496.473 ng/mL
Phase 2 N=264 Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 6 — 70.49; 81.16; 76.81; 29.23 percentage of participants
Phase 2 N=175 Treatment Interruption of Natalizumab
Relapsing Remitting Multiple Sclerosis
Primary: Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance…
Phase 2 N=37 Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia
Primary: Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass — 8; 6; 5; 3 participants